MRG-001
Acute Respiratory Distress Syndrome (ARDS)
Key Facts
About MedRegen
MedRegen is a private, clinical-stage biotech focused on regenerative medicine via a novel small molecule, MRG-001. The company's platform leverages endogenous bone marrow stem cells, mobilizing them to sites of injury to promote repair and modulate inflammation. Its lead asset is in Phase II trials for Acute Respiratory Distress Syndrome (ARDS) and wound healing, with a preclinical candidate, MRG-002, in development. The company operates with private investment and has established key partnerships for manufacturing and clinical execution.
View full company profileAbout MedRegen
MedRegen is a private, clinical-stage biotech focused on regenerative medicine via a novel small molecule, MRG-001. The company's platform leverages endogenous bone marrow stem cells, mobilizing them to sites of injury to promote repair and modulate inflammation. Its lead asset is in Phase II trials for Acute Respiratory Distress Syndrome (ARDS) and wound healing, with a preclinical candidate, MRG-002, in development. The company operates with private investment and has established key partnerships for manufacturing and clinical execution.
View full company profileOther Acute Respiratory Distress Syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| FX06 | F4 Pharma | Phase 1/2 |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| RP-323 | PhorMed | Phase 2 |
| BXT Oxygen Therapeutic | BioXyTran | Pre-clinical/Clinical |
| Remestemcel-L | Mesoblast | Phase 3 |